IDEAS home Printed from https://ideas.repec.org/a/epw/ejmed0/v4y2022i6id41477.html

PARP Inhibitor for Ovarian Cancer Therapy

Author

Listed:
  • I Nyoman Bayu Mahendra

    (Sanglah General Hospital, Indonesia)

  • William Alexander Setiawan

    (Sanglah General Hospital, Indonesia)

Abstract

Almost all ovarian cancers are comprised of epithelial ovarian cancer (EOC). Approximately 80% of patients with EOC initially respond to standard cytoreductive therapy and postoperative platinum-based chemotherapy. However, due to drug resistance in high-grade serous ovarian cancer (HGSOC), recurrence is almost inevitable. Recently, the nuclear enzyme poly (ADP ribose) polymerase (PARP) represents a surprisingly new target in EOC therapy. Inhibitors of PARP have demonstrated promising efficacy in the treatment of EOC. Studies on Olaparib, in particular, hastened its approval in the USA and Europe. The main topics of this study are the pre-clinical evidence, ongoing clinical studies, recent advancements in PARP inhibitor technology, and their potential future roles in clinical care for EOC patients.

Suggested Citation

  • I Nyoman Bayu Mahendra & William Alexander Setiawan, 2022. "PARP Inhibitor for Ovarian Cancer Therapy," European Journal of Medical and Health Sciences, European Open Science, vol. 4(6), pages 1-7, October.
    • Handle: RePEc:epw:ejmed0:v:4:y:2022:i:6:id:41477
    DOI: 10.24018/ejmed.2022.4.6.1477
    as

    Download full text from publisher

    File URL: https://eu-opensci.org/index.php/ejmed/article/view/41477
    File Function: Abstract page
    Download Restriction: no
    File URL: https://eu-opensci.org/index.php/ejmed/article/download/41477/9621
    File Function: Full text
    Download Restriction: no
    File URL: https://libkey.io/10.24018/ejmed.2022.4.6.1477?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:ejmed0:v:4:y:2022:i:6:id:41477. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support (email available below). General contact details of provider: https://eu-opensci.org/index.php/ejmed .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.